Nektar Therapeutics is well-respected as a partner-of-choice by the world's leading pharmaceutical and biotechnology companies. Our platform technologies are validated and used in many of today's most widely-prescribed treatments. As a result, industry returns to us time and time again to co-develop the next-generation of successful therapies designed to meet critical medical needs.
Partial List of Nektar Therapeutics Partners
Our strategic partnerships range from clinical collaborations, joint discovery and co-development to licensing and royalty arrangements with leading pharmaceutical and biotech companies.
Lisa Decker leads Business Development for Nektar and is responsible for partnering activities and strategy. Since joining Nektar in 2008, Dr. Decker has held positions of increasing importance throughout the organization including alliance management, business strategy and operations, and program management. Dr. Decker led negotiations for the broad-based clinical collaboration with Bristol Meyers Squibb for NKTR-214, research collaborations for NKTR-214 with partners such as Takeda and Nouscom, and the NKTR-358 co-development/co-promotion deal with Lilly.
Prior to joining Nektar, Dr. Decker was Associate Director of Technology Licensing at the University of Massachusetts Medical School where she lead the partnering and intellectual property strategy efforts for a diverse array of early stage technologies ranging from medical devices to novel therapeutics, including the University's Nobel prize winning RNAi portfolio. Dr. Decker holds a Ph.D. in Immunology from Tufts University School of Medicine and conducted her postdoctoral training at Harvard Medical School.